An experimental skin cream altered molecular markers associated with aging and inflammation in an early human trial, according to preliminary data released by its developer this week.
uncertain
cream → alter → developer
Rubedo Life Sciences, a biotechnology company based in Mountain View, California, tested its investigational treatment, RLS-1496, in patients with eczema and other skin conditions.
asserted
Sciences → base → eczema
In an analysis of 11 paired skin samples from patients with atopic dermatitis, researchers reported that four weeks of treatment was associated with an average 2.1-year decrease in measured epigenetic skin age — an estimate based on age-related changes in DNA.
asserted
weeks → pair → DNA
Rubedo CEO Dr. Frederick Beddingfield said the "significant" early findings warrant further investigation.
asserted
findings → say → investigation
"This is one of the few drugs developed for aging in general and with AI to show positive data in humans in multiple indications and to show a reduction in skin age," Beddingfield told Fox News Digital.
asserted
Beddingfield → develop → Digital
He believes the early results will translate into "clinical improvements with longer-term treatment."
The latest skin-aging findings have been presented at a scientific conference, but have not yet been published as a full peer-reviewed study.
asserted
findings → believe → study
RLS-1496 is designed to target senescent cells — aging or damaged cells that have stopped dividing, but can release substances that promote inflammation.
asserted
that → design → inflammation
The drug targets a protein called GPX4, which helps cells respond to stress.
asserted
cells → target → stress
Researchers are studying whether blocking it can clear away damaged, aging cells while helping healthier cells survive.
asserted
cells → study → cells
Beddingfield described the approach as targeting cellular aging rather than simply treating its outward effects.
asserted
Beddingfield → describe → effects
"It's a bit like 'what does not kill you makes you stronger' for those surviving cells," he added.
asserted
he → kill → cells
Skin samples showed a 10% increase in a type of collagen that helps support the skin, according to the company.
uncertain
that → show → company
Blood tests also showed lower levels of several markers linked to inflammation, although it is not yet clear what those changes mean for patients' health.
asserted
changes → show → health
The preliminary findings come with several limitations.
asserted
findings → come → limitations
The skin-aging analysis included just 11 paired samples and measured biological signs of aging in the skin rather than whether the skin actually looked younger or functioned better.
asserted
skin → include → skin
Treatment lasted only four weeks, so it is not known whether the changes will persist.
asserted
changes → last → weeks
The studies were sponsored by Rubedo, and the latest skin-aging findings have not yet been published as a full peer-reviewed study.
asserted
findings → sponsor → study
"Our next trial will treat for several months," Beddingfield said.
asserted
Beddingfield → treat → months
The treatment is also being tested for other skin issues.
asserted
treatment → test → issues
In a separate early-stage study of 22 patients with actinic keratosis — rough, precancerous skin patches caused by sun exposure — the company reported a 49% average reduction in lesions after 28 days of treatment.
asserted
company → cause → treatment
The open-label study compared treated forearms with untreated forearms rather than a placebo cream.
asserted
study → compare → cream
The cream caused minimal skin irritation, and the drug was detected in the blood of very few participants, according to the company.
uncertain
drug → cause → company
"With topical application, we have seen very little risk," Beddingfield said.
asserted
Beddingfield → see → risk
"Local irritation is rarely seen and generally mild when it occurs, and no one has discontinued treatment to date.
asserted
one → see → date
Very few subjects show any drug in their blood after skin application.
asserted
subjects → show → application
"
Rubedo is also beginning an early-stage trial of RLS-1496 for androgenetic alopecia, or pattern hair loss.
asserted
Rubedo → begin → alopecia
Beddingfield estimated that potential FDA approval remains three to four years away, pending larger clinical trials.
asserted
approval → estimate → trials
The Aporia
